COMMUNIQUÉS West-GlobeNewswire

Palvella Therapeutics Announces Proposed Public Offering
24/02/2026
WAYNE, Pa., Feb. 24, 2026 (GLOBE NEWSWIRE) -- Palvella Therapeutics, Inc. (“Palvella”) (Nasdaq: PVLA), a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapies to treat [...]
Serina Therapeutics Announces Dosing of First Patient in Phase 1b Registrational Trial of SER-252 for Advanced Parkinson’s Disease
24/02/2026
- Blinded evaluation of safety and tolerability data by the Safety Monitoring Committee from Cohort 1 and advancement to Cohort 2 is expected in 3Q 2026 – - Advancement reflects continued execution of capital-efficient [...]
BridgeBio Reports Fourth Quarter and Full Year 2025 Financial Results and Commercial Updates
24/02/2026
$154.2 million in total fourth quarter revenues, net, and $502.1 million in full year revenues, net, primarily comprised of net product revenue of $146.0 million and $362.4 million, respectively BridgeBio reported three [...]
Rapid Micro Biosystems to Announce Fourth Quarter and Full Year 2025 Financial Results on March 12, 2026
24/02/2026
LEXINGTON, Mass., Feb. 24, 2026 (GLOBE NEWSWIRE) -- Rapid Micro Biosystems, Inc. (Nasdaq: RPID) (the “Company”), an innovative life sciences technology company providing mission-critical automation solutions to [...]
Spyre Therapeutics to Participate in Upcoming March Investor Conferences
24/02/2026
WALTHAM, Mass., Feb. 24, 2026 (GLOBE NEWSWIRE) -- Spyre Therapeutics, Inc. (NASDAQ: SYRE), a clinical-stage biotechnology company pioneering long-acting antibodies and antibody combinations to redefine the standard of [...]
Teva to Present at the Upcoming Investor Conferences in March
24/02/2026
PARSIPPANY, N.J. and TEL AVIV, Israel, Feb. 24, 2026 (GLOBE NEWSWIRE) -- Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) today announced that Richard Francis, Teva's President and CEO, will participate in the [...]
FibroBiologics Reports Full Year 2025 Financial Results and Provides Corporate Update
24/02/2026
Planning for phase 1/2 clinical trial initiation in Australia utilizing CYWC628 to treat diabetic foot ulcers in the first half of 2026 Improved balance sheet through multiple direct offerings; completed payments of [...]
Day One Reports Fourth Quarter and Full Year 2025 Financial Results and Reaffirms 2026 Outlook and Revenue Guidance
24/02/2026
OJEMDA™ 2025 momentum reflected by Q4 and full year net product revenues of $52.8 million and $155.4 million, respectively 2026 U.S. net product revenue projected at $225 - $250 million Expanded pipeline with January [...]
Jasper Therapeutics to Present at 46th Annual TD Cowen Healthcare Conference
24/02/2026
REDWOOD CITY, Calif., Feb. 24, 2026 (GLOBE NEWSWIRE) -- Jasper Therapeutics, Inc. (Nasdaq: JSPR) (Jasper), a clinical stage biotechnology company focused on development of briquilimab, a novel antibody therapy targeting [...]
Werewolf Therapeutics Announces Plan to Explore Strategic Alternatives
24/02/2026
WATERTOWN, Mass., Feb. 24, 2026 (GLOBE NEWSWIRE) -- Werewolf Therapeutics, Inc. (Nasdaq: HOWL) (the “Company” or “Werewolf”), an innovative biopharmaceutical company pioneering the development of therapeutics engineered [...]
Bioventus to Report Fourth Quarter of Fiscal Year 2025 Financial Results on March 5, 2026
24/02/2026
DURHAM, N.C., Feb. 24, 2026 (GLOBE NEWSWIRE) -- Bioventus Inc. (Nasdaq: BVS) (“Bioventus” or the “Company”) , a global leader in innovations for active healing, today announced that it will report financial results for [...]
AB Science announces the identification of a plasma biomarker that indicates the activity of masitinib in treating ALS
24/02/2026
PRESS RELEASE AB SCIENCE ANNOUNCES THE IDENTIFICATION OF A PLASMA BIOMARKER THAT INDICATES THE ACTIVITY OF MASITINIB IN TREATING AMYOTROPHIC LATERAL SCLEROSIS, AND THAT IS CAPABLE OF IDENTIFYING PATIENTS WITH PRO [...]
Research in carrot and cherry crops to strengthen local food security
24/02/2026
VANCOUVER, British Columbia, Feb. 24, 2026 (GLOBE NEWSWIRE) -- As climate change continues to disrupt Canada’s agricultural stability, Genome British Columbia (Genome BC) is funding two research collaborations to [...]
Linnaeus Therapeutics Awarded Up to $22 Million from ARPA-H to Advance LNS8801 for Healthspan Preservation
24/02/2026
ARPA-H PROSPR program to support accelerated development of LNS8801 to promote healthy aging HADDONFIELD, N.J., Feb. 24, 2026 (GLOBE NEWSWIRE) -- Linnaeus Therapeutics, Inc., a privately held company focused on the [...]
AB Science annonce l'identification d'un biomarqueur plasmatique marqueur de l'activité du masitinib dans le traitement de la SLA
24/02/2026
COMMUNIQUÉ DE PRESSE AB SCIENCE ANNONCE L'IDENTIFICATION D'UN BIOMARQUEUR PLASMATIQUE MARQUEUR DE L'ACTIVITÉ DU MASITINIB DANS LE TRAITEMENT DE LA SCLÉROSE LATÉRALE AMYOTROPHIQUE, ET CAPABLE D'IDENTIFIER LES PATIENTS [...]
Validic Adds Epic Toolbox, Generative AI, Multi-Instance Support, and More to Existing Epic Integration
24/02/2026
New Epic-integrated features including Toolbox alignment, multi-instance support, AI-powered RPM summarization, and expanded wearable integrations help health systems ensure timely, risk-reducing care LOS ANGELES, Feb. [...]
Cosmos Health Appoints Globally Recognized AI-Driven Drug Discovery and Clinical-Stage Biotech Expert Dr. Dimitrios Iliopoulos to Advisory Board
24/02/2026
CHICAGO, Feb. 24, 2026 (GLOBE NEWSWIRE) -- Cosmos Health Inc. ("Cosmos Health" or the “Company”) (NASDAQ:COSM) , a diversified, vertically integrated global healthcare group, today announced the appointment of Dr. [...]
Empathy in Medicine Initiative Announces Student Chapter Program to Empower High School and College Students in Healthcare Leadership
24/02/2026
EMI launches Student Chapter Program to support students in starting empathy-focused healthcare clubs and community projects Empathy in Medicine Initiative (EMI) Image NEW YORK, Feb. 24, 2026 (GLOBE NEWSWIRE) -- The [...]
Surgery Partners, Inc. Announces Fourth Quarter 2025 Earnings Release Date and Conference Call Details
24/02/2026
BRENTWOOD, Tenn., Feb. 24, 2026 (GLOBE NEWSWIRE) -- Surgery Partners, Inc. (NASDAQ:SGRY) ("Surgery Partners" or the "Company"), a leading short-stay surgical facility owner and operator, announced the Company will [...]

Pages